ABT Abbott Laboratories

$ABT Rothschild & Co Redburn moved Abbott to Buy on Friday, lifting its target to 127 from 119 (per Benzinga, via MarketBeat). That is about 30 percent upside from Friday's close near 97.50. What stands out is how far the tape and the Street have drifted apart. The stock is down about 22 percent this year and still sits below its 50-day average. Meanwhile 21 analysts rate it a Buy, with an average target of 119.80. The validator is the Q3 print on Oct 21: consensus looks for adjusted EPS of 1.43 against 1.30 a year ago, and the company guides 5.45 to 5.60 for fiscal 2026. Tracking this into the Oct 21 print.

$ABT: the Connoly suit alleges Abbott failed to warn a Libre 2 could read normal while glucose was actually elevated. She says she relied on those readings for a day before ICU care for DKA. Nothing to claim. Open Class Actions.

$ABT staying in the green, holding steady, & doing exactly what a quality large cap should do on a day like today when all of the major indexes are red. Very optimistic about earnings for us next week. Wishing a great weekend to all in the meantime!

$ABT love seeing us have a bounce back day back above $100+ like this - we have been needing it 🥂

$ABT Wow! Is it really a green day for us?!? I must be dreaming! 🥂 Many more to come as we grind our way back towards $130+. Have a great weekend all 😎

$ABT breaks the support of 98 and drifts lower towards ER, hope ER number will reverse the downwards trend

$ABT $IHI $XLV Abbott Laboratories (ABT) - Weekly Chart Improving momentum, with price so far holding that round psychological $100 trading number. Note: Earnings wildcard catalyst scheduled mid Oct.

$ABT reports Wednesday before the open, consensus at 1.42 dollars EPS on 12.97 billion dollars in revenue, up 14.1% YoY. Diagnostics is carrying the growth in the models, 3.29 billion dollars, up 45.9%, and U.S. diagnostics is seen at 1.85 billion, up 108.3%. International diagnostics is only modeled up 5.7%. Nutrition is at 2.21 billion, up 2.7%, diabetes care at 2.20 billion, up 6.8%. Pretty different mix than the slow, balanced Abbott print people are used to.

$ABT $ABBV ABT was a great stock prior to 2013 and then it split giving biggest drug (Humira) to new company Abbvie. Ever since then, ABT has not been that good while Abbvie has been GREAT. 1 year return: ABT ..... -22% ABBV ...... +23% 10 year return: ABT ...... 142% ABBV ..... 349% Shame on Miles White to mess up a great company as Abbott, Mr. Abbott is turning is his grave.

$ABT close above 20MA would be the first in weeks. The fact it didn't touch the gap below is bullish to me. Next two targets are in the chart.

$ABT | BULLISH 🐂 🏢 Business & Value: Premier healthcare & medical device titan! Q2 revenue surged +13.0% YoY to $12.59B ($1.31 EPS beat), prompting management to raise full-year EPS guidance to $5.45–$5.60! 🚨 Chart Setup: Textbook 1W macro trendline retest holding $96.00–$99.00 support! Smart money sweeping long-dated March 2027 $100C LEAPS ($214.6K) as price coils right on top of the primary volume shelf! 📈💥 🎯 Key Levels to Confirm: • Bull Trigger: Reclaim $102.50 ➡️ Targets: $107.50 / $112.50 / $123.78+ 🚀 • Bear Trigger: Hard break below $93.00 🛑 • Analyst Consensus: Strong Buy with $120.00–$130.00 price targets! Watching for the healthcare value bounce launch! 👀⚡ #ABT #stocks #hovdid

$ABT Dow turned green but this took a noose dive, making sense??! Has been very weak lately for some reason

$ABT they need to be doing some serious stock buy backs at these prices…. They did alittle last quarter but they really need to do more and get dilution from SJM deal back under control

$ABT Was expecting a lift from SimpleScreen CRC rollout that didn't happen, now has to wait for ER for next move

$ABT: 167 vs. 700. The Connoly complaint alleges a Libre 2 sensor showed a normal 167 mg/dl while hospital staff measured blood sugar near 700, and the user landed in ICU with DKA. Allegations only, no settlement. Open Class Actions.

$ABT case watch: Connoly v. Abbott, 2:26-cv-00840, is captioned a class action but pleads only individual Louisiana product liability claims, with no Rule 23 class definition. Likely a mass tort path, nothing to claim. Open Class Actions.

$ABT literally who is left that is still selling. This thing has been a pig for 5 years straight, at some point you literally have to run out of sellers

$ABT QUICK all eyes and strong buys to PLUME to explode to 100$ Updated valuation! NICE!! THE TRAIN IS LEAVING!

$ABT Guys ILs companies with solid working tech, with proven results are worth over $1.X billion, so off rip PDSB should be worth $11.50. If the NIH and IBRX is messing with them and the original tech pass MRK hands, $1.20 is cheap. Mastering how to handle and boost Interleukins to fight cancers are always game changers. See IBRX, SLS, IOVA, etc. You're welcome!

$ABT | Rothschild Redburn Upgrades Abbott Labs to Buy with $127 PT on Medical Devices Strength and Diagnostics Growth Rothschild Redburn stays bullish as Medical Devices momentum and Exact Sciences integration drive stronger growth outlook. 🔹 Follow for more analyst insights on other tickers.